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Abstract
Pyridoxine 5′-phosphate oxidase (PNPO) is an enzyme that converts pyridoxine 5′-phosphate into pyridoxal 5′-
phosphate (PLP), an active form of vitamin B6 implicated in several types of cancer. However, the role of PNPO and its
regulatory mechanism in epithelial ovarian cancer (EOC) are unknown. In the present study, PNPO expression in human
ovarian tumour tissue and its association with the clinicopathological features of patients with EOC were examined.
Further, the biological function of PNPO in EOC cells and in xenograft was evaluated. We demonstrated for the ﬁrst time
that PNPO was overexpressed in human EOC. Knockdown of PNPO induced EOC cell apoptosis, arrested cell cycle at
G2/M phase, decreased cell proliferation, migration and invasion. Xenografts of PNPO-shRNA-expressing cells into the
nude mouse attenuated tumour growth. PNPO at mRNA and protein levels in EOC cells was decreased after
transforming growth factor-β1 (TGF-β1) treatment. The inhibitory effect of TGF-β1 on PNPO expression was abolished in
the presence of SB-431542, a TGF-β type I receptor kinase inhibitor. Moreover, we found that TGF-β1-mediated PNPO
expression was at least in part through the upregulation of miR-143-3p. These data indicate a mechanism underlying
PNPO regulation by the TGF-β signalling pathway. Furthermore, PLP administration reduced PNPO expression and
decreased EOC cell proliferation, suggesting a feedback loop between PLP and PNPO. Thus, our ﬁndings reveal that
PNPO can serve as a novel tissue biomarker of EOC and may be a potential target for therapeutic intervention.
Introduction
Human ovarian cancer (OC) is the most deadly disease
in women. Histologically, there are three main types of
cancer: epithelial, sex cord-stromal and germ cell
tumours1–3. Epithelial ovarian cancer (EOC), derived from
the epithelial cells of the ovary or the fallopian tube4,
accounts for more than 90% of total OC and occurs most
commonly in postmenopausal women5. About 70% of
EOCs are at an advanced stage because of an inability to
detect the disease early due to an absence of symptoms
and lack of an effective diagnostic marker6,7, making it the
most lethal gynaecological malignancy. As such, there is a
critical need to identify biomarkers for early detection of
OC and possible targets for therapeutic intervention.
Vitamin B6 exist as six vitamers, including pyridoxine
(PN), pyridoxamine (PM), pyridoxine 5′-phosphate (PNP),
pyridoxamine 5′-phosphate (PMP), pyridoxal 5′-phos-
phate (PLP) and pyridoxal (PL)8. Dietary PN and PM
serve as the main source of PNP and PMP. Oxidation of
PNP and PMP produces PLP which can be further
metabolized to PL through enzymatic hydrolysis9,10. PLP,
an active form of vitamin B6, is an essential cofactor
required by many enzymes for metabolic processes
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including metabolism of carbohydrates, fats and pro-
teins11–13. Pyridoxine 5′-phosphate oxidase (PNP oxidase,
PNPO), also known as PMP oxidase, is a key enzyme in
vitamin B6 metabolism and converts PNP and PMP into
PLP14. The PNPO gene is located on chromosome
17q21.3215 and the level of PNPO mRNA expression is
relatively high in human liver, skeletal muscle and kidney,
but low in lung and ovary16. PNPO has known to play a
role in human epilepsy. PNPO deﬁciency, due to muta-
tions in the PNPO gene, has been widely reported in
neonatal/infantile epileptic encephalopathy17,18. Addi-
tionally, few reports indicate that PNPO has been impli-
cated in breast and colorectal cancers19–21. However, it
remains unknown whether PNPO plays a role in the
development and progression of EOC.
Transforming growth factor-β (TGF-β) is an important
cytokine involved in a variety of cellular processes and has
been implicated in carcinogenesis22. TGF-β plays key
roles in the regulation of many biological functions,
including cell proliferation, migration, invasion and
apoptosis and has dual actions in tumour suppression and
tumour promotion under certain circumstances23,24. The
TGF-β subfamily members (TGF-β1, TGF-β2 and TGF-
β3) activate the downstream Smad transducer proteins,
such as Smad2 and Smad3, by the heteromeric complexes
of its type I (TβRI) and type II (TβRII) receptors25,26.
Clinical studies showed that the dysregulation of TGF-β
signalling may contribute to the development of OC and
is associated with metastasis and survival27,28. However,
whether TGF-β regulates PNPO expression in OC is
largely unknown. Following our recent reports that
human cystatin B, β-2-microglobulin and cytidine
monophosphate kinase are ovarian tumour progression
markers and are regulated by TGF-β129–31, we speculate
that PNPO may be another EOC biomarker and that it
may also be regulated by TGF-β signalling.
In this study, we examine whether PNPO expression
would be associated with clinicopathological features of
patients with EOC and the change of its expression level
would impact biological processes characteristic of cancer
progression including cell proliferation, migration, inva-
sion and apoptosis in vitro and tumour growth in vivo.
We also examine the mechanism of how PNPO expres-
sion is regulated by the TGF-β signalling pathway.
Results
PNPO is overexpressed in human epithelial ovarian cancer
Immunohistochemistry (IHC) showed that PNPO
staining intensity was greater in human ovarian surface
epithelial tumours (Fig. 1a and Supplementary Figure S1).
The immunoreactive staining of PNPO was weak in
normal tissues of the ovary and the fallopian tube and
benign tumour, moderate in borderline tumour and
strong in malignant tumours, including serous, mucinous,
endometrioid, clear cell and transitional cell carcinomas.
The positive staining was mainly distributed in the cyto-
plasm of the EOC cells. We also evaluated the association
between PNPO protein expression and the clinical char-
acteristics of patients with OC using tissue microarray
(Fig. 1b and Supplementary Table S1). The positive rate of
PNPO protein expression was slightly higher in patients at
age> 45 vs. ⩽45 (P= 0.015). By analysis of histological
types, we found that PNPO protein expression was sig-
niﬁcantly associated with surface epithelial malignant
tumours compared with sex cord-stromal and germ cell
tumours (P< 0.001, Fig. 1b). However, there was no
association between subtypes of epithelial malignant
tumours, including serous, mucinous and endometrioid
adenocarcinomas, and clear and transitional cell carci-
nomas (Supplementary Table S1). PNPO protein expres-
sion was also affected by the grades (P= 0.024). Multiple
comparisons showed that PNPO protein expression was
not associated with the clinical stages of primary tumour
site and FIGO or lymph node metastasis in patients with
OC (P> 0.05). Next, we examined the expression of
PNPO at mRNA and protein levels in epithelial serous
tumours. The PNPO mRNA expression was higher in
serous malignant tumour compared with the normal tis-
sue of the ovary (P< 0.05, Fig. 1c). Overexpression of
PNPO protein in ovarian serous malignant tumour was
conﬁrmed by western blot (Fig. 1d). Semi-quantitative
analysis of the relative optical density of protein bands
showed that the expression of PNPO protein was sig-
niﬁcantly high in malignant tumours than in the normal
ovarian tissue and benign tumour (P< 0.05, Fig. 1e). Since
the high-grade serous carcinoma may derive from the
fallopian tube32, next we examined the expression levels
of PNPO protein in the tissues of the normal fallopian
tube and ovary as well as serous malignant tumours.
Western blot analysis showed that the expression of
PNPO protein was much higher in serous malignant
tumours than the normal fallopian tube and ovarian tis-
sues (P< 0.001, Supplementary Figure S2a and S2b).
Furthermore, the expression of PNPO protein was higher
in EOC cell lines OVCAR-3 and SK-OV-3, but not in
other two adenocarcinoma cell lines CAOV-3 and A2780
and a clear cell line ES-2, compared with non-tumorous
human ovarian surface epithelial cell line HOSEpiC (P<
0.05; Supplementary Figure S3a and S3b).
Knockdown of PNPO inhibits ovarian cancer cell
proliferation and arrests cell cycle
Since PNPO was overexpressed in EOC, a loss-of-
function approach was used to evaluate the functional
signiﬁcance of PNPO in OVCAR-3 and SK-OV-3 cells.
Quantitative real-time PCR (qRT-PCR) and western blot
conﬁrmed the efﬁcacy of PNPO silencing at the mRNA
and protein levels in cells transfected with PNPO-siRNA
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Fig. 1 (See legend on next page.)
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compared to cells transfected with negative control (NC)
siRNA (Supplementary Figure S4a−S4d). Further, cell
proliferation was signiﬁcantly decreased after PNPO-
siRNA transfection in OVCAR-3 cells for 72 h and in SK-
OV-3 cells for 48 and 72 h (P< 0.05, Supplementary
Figure S4e and S4f).
PNPO-shRNA constructs contained green ﬂuorescent
protein (GFP) and the expression of GFP in PNPO-
shRNA-expressing cells was relatively stable in SK-
OV-3 and OVCAR-3. Approximately 99% cells were
GFP-positive without morphological change after ﬁve
passages (Fig. 2a and b). Knockdown of PNPO was con-
ﬁrmed by qRT-PCR (Fig. 2c and d) and western blot
(Fig. 2e−h). Compared with control cells (NC), a sig-
niﬁcant decrease in cell growth was observed in PNPO-
shRNA-expressing cells (shPNPO) at 24, 48 and 72 h
post-seeding (P< 0.05, Fig. 2i and j).
Flow cytometry revealed that the population of SK-OV-
3 NC and shPNPO cells was 52.6 and 49.0% in G1 phase,
33.3 and 23.4% in S phase and 14.2 and 25.1% in G2/M
phase, respectively (Fig. 2k and m), whereas the popula-
tion of OVCAR-3 NC and shPNPO cells was 56.7 and
59.3% in G1 phase, 34.8 and 30.1% in S phase and 8.5 and
10.6% in G2/M phase, respectively (Fig. 2l and n). These
data indicate that the knockdown of PNPO induces EOC
cell cycle arrest at G2/M phase.
Knockdown of PNPO inhibits migration and invasion
of ovarian cancer cells
PNPO suppression signiﬁcantly inhibited wound heal-
ing in SK-OV-3 PNPO-shRNA-expressing (shPNPO) cells
compared with NC cells after monolayer scratch (Fig. 3a
and b). Further, migration assays using Transwell revealed
that the number of migrating cells was reduced to 49% in
shPNPO cells compared with NC cells at 48 h after
seeding (Fig. 3c and d). A similar result was found in
OVCAR-3 PNPO-shRNA-expressing cells (Supplemen-
tary Figure 5a and 5b).
We also observed a reduced number of invading cells in
SK-OV-3 PNPO-shRNA expressing (shPNPO) cells
compared to NC cells. The number of invading cells was
reduced to 52% in shPNPO cells compared with NC cells
at 48 h after seeding (Fig. 3e and f). Again, a similar result
was found in OVCAR-3 PNPO-shRNA expressing cells
(Supplementary Figure 5c and 5d). Collectively, these data
indicate that the knockdown of PNPO inhibits cell
migration and invasion.
Knockdown of PNPO promotes ovarian cancer cell
apoptosis
Flow cytometry analysis revealed that the number of
apoptotic cells was signiﬁcantly increased in SK-OV-3
shPNPO cells compared with NC cells (P< 0.05, Fig. 4a
and b). SK-OV-3 shPNPO cells also had a high level of
cleaved caspase-3 protein compared with NC cells (Fig. 4c
and d). Further, the expression of pro-apoptotic factor
Bax was increased, while the expression of anti-apoptotic
factor Bcl-2 was decreased, in shPNPO cells compared
with NC cells (Fig. 4e). The ratio of Bcl-2/Bax was sig-
niﬁcantly reduced (P< 0.05, Fig. 4f), conﬁrming the
induction of apoptosis after PNPO knockdown.
Knockdown of PNPO suppresses tumour growth in an
animal xenograft model
Tumour volume from PNPO-shRNA mice was smaller
than tumour volume from control SK-OV-3 (NC, control)
mice (Fig. 5a). The average of tumour volume in control
mice was about 150 mm3, whereas the tumour volume in
PNPO-shRNA mice was less than 50mm3 (P< 0.05,
Fig. 5b). Tumour volume signiﬁcantly increased in control
mice compared to PNPO-shRNA mice by day 30 post-
injection, persisting to the end of observation at day 40 (P
< 0.05, Fig. 5c). Despite the difference in tumour volume,
mouse body weight between the two groups was not
different (Fig. 5d). Additionally, PNPO protein expression
was almost undetectable in PNPO-shRNA tumours
compared with control tumours (P< 0.01, Fig. 5e and f),
consistent with the low levels of immunoreactive staining
of PNPO protein in PNPO-shRNA tumour sections
(Fig. 5g). Moreover, quantitative analysis of proliferative
marker Ki67 and PNPO-positive cells showed a signiﬁcant
decrease in the number of Ki-67-positive cells and PNPO-
shRNA-expressing cells after PNPO knockdown (P<
0.05, Fig. 5h and i). These data indicate that PNPO affects
tumour growth and cell proliferation and may inﬂuence
ovarian tumorigenesis.
(see ﬁgure on previous page)
Fig. 1 PNPO expression in human ovarian tissues. a Immunohistochemistry staining of PNPO. Representative images of PNPO expression in the
normal tissues of the fallopian tube and the ovary, serous and mucinous benign, borderline and malignant tumours, and endometrioid, clear cell and
transitional cell malignant tumours are shown. A brown colour in an epithelial cell is considered as a positive staining. Original magniﬁcation, ×400.
Scale bar, 50 µm. b Positive rate of PNPO protein expression in patients with ovarian tumours. Epithelial, surface epithelial-stromal tumours; Sex cord,
sex cord-stromal tumours; Germ cell, germ cell tumours. c PNPO mRNA expression detected by qRT-PCR in the normal ovarian tissues, ovarian serous
benign, borderline and malignant tumours (n = 3 each). d PNPO protein expression detected by western blot analysis in normal ovarian tissue (#1–3),
ovarian serous benign tumours (#4–6), borderline tumours (#7–9) and malignant (#10–12) tumours. e Semi-quantitative analysis of the relative optical
density of protein bands in d. Data are presented as mean ± SEM. *P < 0.05; **P < 0.01
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PNPO expression and cell proliferation are inﬂuenced
by vitamin B6 vitamers
To evaluate the enzymatic activity of PNPO, we ﬁrst
measured the concentrations of PN, PM, PLP and PL vita-
mers in the cytosol and culture medium. The basal level of
cytosolic PN, PM and PLP was higher in SK-OV-3 cells
compared with OVCAR-3 and HOSEpiC cells (Fig. 6a).
Because PN and PM are essential for living cells during
culture, a commercial culture medium must contain PN and
PM. Thus, the amount of consumed PN and PM were cal-
culated by the concentrations of PN and PM in the original
medium minus the concentrations of that measured in the
cultured medium. We found that SK-OV-3 cells consumed
more PN and PM from culture media after 48 h incubation
and produced more cytosolic PLP (P< 0.05, Fig. 6b). These
data indicate that SK-OV-3 cells may have more PNPO
activity, which is consistent with the high levels of PNPO
protein expression in SK-OV-3 cells compared with
OVCAR-3 and HOSEpiC cells (Supplementary Figure S3).
Treatment of SK-OV-3 cells with PLP and PN revealed
that PLP suppressed PNPO expression in time- and dose-
dependent manners (Fig. 6c and d). Administration of
PLP (0.5 mg/ml) downregulated, whereas administration
of PN (0.5 mg/ml) upregulated PNPO protein expression
in SK-OV-3 and OVCAR-3 cells (Fig. 6e−h), indicating a
feedback loop between PNPO and vitamers.
Subsequently, we investigated the extent to which PLP
inﬂuences cell proliferation and found that compared with
control groups (Blank and HCl vehicle), SK-OV-3 cells at
48 and 72 h (P< 0.01, Fig. 6i) and OVCAR-3 cells at 24, 48
and 72 h (P< 0.01, Fig. 6j) had reduced cell growth after
PLP administration. We also observed a decrease in cell
proliferation in both SK-OV-3 and OVCAR-3 cells at 48
and 72 h after PN administration (P< 0.01, Fig. 6i and j).
Higher PN may stimulate PNPO expression, which in
turn converts it into PLP, whereas an increase in PLP
negatively regulates PNPO expression, with downstream
impact on cell proliferation. These data further conﬁrm
that there is a feedback loop between PNPO and vitamers.
PNPO expression is regulated by the TGF-β signalling
pathway via miR-143-3p
Since TGF-β plays a key role in ovarian tumorigenesis
and PNPO is overexpressed in OC, we next investigated
the inﬂuence of TGF-β signalling on the PNPO expression
in two EOC cells (SK-OV-3 and OVCAR-3). PNPO
expression in SK-OV-3 and OVCAR-3 cells was sig-
niﬁcantly decreased after TGF-β1 treatment both at the
mRNA (Fig. 7a) and protein (Fig. 7b and c) levels (P<
0.05). Because Smad2 is a transducer protein and is acti-
vated upon TGF-β1 treatment, the increased phosphor-
ylation of Smad2 can be considered as a cell’s
responsiveness to TGF-β1. Indeed, p-Smad2 was
increased in SK-OV-3 and OVCAR-3 cells after TGF-β1
treatment (1 and 10 ng/ml) for 24 h (Fig. 7b).
By blocking the TGF-β signalling pathway using a TGF-
β type I receptor kinase inhibitor SB-431542, we found
that the effect of TGF-β1 on PNPO expression at the
mRNA and protein levels was abolished (Fig. 7d−f).
Interestingly, a decrease in PLP levels in the cytosol and
an increase in PLP levels in the media were observed in
SK-OV-3 cells after 10 ng/ml TGF-β1 treatment (Sup-
plementary Figure S6), suggesting that TGF-β1 may sti-
mulate the PLP secretion. These actions of TGF-β1 were
also abolished by SB-431542 (Supplementary Figure S6),
indicating that PNPO expression and vitamin B6 meta-
bolism are mediated by the TGF-β signalling pathway.
Using miRWalk 2.0 database33, we found that PNPO is a
potential target of miR-143-3p. In order to conﬁrm the
interaction of miR-143-3p with PNPO mRNA, we con-
structed two plasmids: a wild-type PNPO 3′-UTR con-
taining a miR-143-3p binding site (position at 1260−1266
of 3′-UTR) and a mutated PNPO 3′-UTR in which the
binding site was changed (Fig. 7g). Dual-luciferase assay
conﬁrmed that wild-type 3′-UTR, not mutated 3′-UTR,
bound to PNPO 3′-UTR (Fig. 7h). Treating SK-OV-3 cells
with miR-143 mimics resulted in decreased PNPO protein
expression (P< 0.05; Fig. 7i and j), whereas treating cells
with miR-143 inhibitor (anti-miR-143) resulted in
increased PNPO protein expression (Fig. 7k). Notably,
TGF-β1 enhanced primary and mature miR-143-3p
expression (P< 0.05; Fig. 7l and m). These data suggest
that TGF-β-mediated PNPO expression is at least in part
controlled through the upregulation of miR-143-3p.
To determine the correlation between PNPO mRNA
expression and miR-143 expression in patients with
ovarian tumours, we performed a qRT-PCR in ovarian
tissues of 14 patients (4 benign, 3 borderline, 7 malignant
(see ﬁgure on previous page)
Fig. 2 Effect of PNPO-shRNA on cell proliferation and cell cycle. SK-OV-3 (a, c, e, f, i, k and m) and OVCAR-3 (b, d, g, h, j, l and n) PNPO-shRNA-
expressing cells (shPNPO) are generated. a, b The phase contrast and ﬂuorescent images of shPNPO cells at ﬁfth passage are shown. Approximately
99% cells were GFP-positive. c, d PNPO mRNA expression was lower in shPNPO cells than in negative control (NC) cells detected by quantitative qRT-
PCR. e−h PNPO protein expression was decreased in shPNPO cells detected by western blot using a speciﬁc antibody against human PNPO.
Histograms show the semi-quantitative analysis of the relative optical density of protein bands (each n = 3). i and j A time-course study shows the
proliferation of NC and shPNPO cells detected by the WST-1 assay. k and l Cell cycle of NC and shPNPO was determined by ﬂow cytometry.m and n
Histograms show the percentage of the cell population in each phase. *P < 0.05; **P < 0.01; n = 3 independent experiments
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Fig. 3 Effect of PNPO-shRNA on cell migration and invasion. SK-OV-3 PNPO-shRNA-expressing cells (shPNPO) and negative control cells (NC)
were used in experiments. a Wound healing assay. Photos of the wound were taken at 0, 24, 48 and 72 h after scratching. Original ampliﬁcation, ×40.
b Line graph shows the quantitative analysis of the wound healing at different time point. c Transwell assay of cell migration. Photos were taken at
48 h after seeding. Original ampliﬁcation, ×200; scale bar, 50 µm. d Histogram shows the quantitative analysis of migrated cells of c, e Cell invasion
assay. Photos were taken at 48 h after seeding. Original ampliﬁcation, ×200; scale bar, 50 µm. f Histogram shows the quantitative analysis of invaded
cells of e. Data are presented as mean ± SEM. *P < 0.05; **P < 0.01; n = 3 independent experiments
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presented as mean ± SEM. *P < 0.05; **P < 0.01; n = 3 independent experiments
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tumours) and 5 normal controls. We found that there was
a slight negative-correlation in ovarian tissues (n= 19
individuals, Supplementary Figure S7). The high level of
PNPO mRNA expression was also found in serous (n=
41), mucinous (13) and endometrioid (n= 37) adeno-
carcinoma as well as in clear cell carcinoma (n= 8)
compared with normal ovary (n= 4) in the microarray
data sets of Hendrix from Oncomine database
(www.oncomine.org) (Supplementary Figure S8). These
data further conﬁrm the overexpression of PNPO in OC,
indicating that PNPO may play a role in OC development.
Next, we examined the effect of PNPO-shRNA on PLP
concentration and Smad2 phosphorylation in EOC cells.
We found that knockdown of PNPO resulted in a
decrease of PM, PLP and PL levels in the cytosol (P< 0.05,
Supplementary Figure S9a), a reduction of PL level in
medium of SK-OV-3 (P< 0.01, Supplementary Fig-
ure S4b), and an increase of PLP level in the medium of
OVCAR-3 (P< 0.01, Supplementary Figure S9b). Silen-
cing of PNPO after PNPO-shRNA infection was con-
ﬁrmed by western blot in OVCAR-3 and SK-OV-3 cells
(Supplementary Figure S9c and S9d). Interestingly, we
also observed an increase of Smad2 phosphorylation after
PNPO knockdown (P< 0.05, Supplementary Figure S9c
and S9d), suggesting that there is a negative feedback loop
between PNPO and TGF-β signalling.
Discussion
Our study provides new insights into the role and
function of PNPO in OC. We demonstrated for the ﬁrst
time that PNPO is overexpressed in EOC. Knockdown of
PNPO affects EOC cell behaviour in vitro and inﬂuences
tumour formation in vivo. Furthermore, PNPO is medi-
ated by the TGF-β signalling pathway through the upre-
gulation of miR-143-3p.
Most studies on PNPO have been conducted in the con-
text of epilepsy development. Deﬁciency or mutation in
PNPO is known to be a cause for neonatal and infantile
epileptic encephalopathy15,34,35. However, the role of PNPO
and the mechanisms underlying the regulation of PNPO in
cancer progression, especially in EOC, are unknown. Our
previously unpublished data in a screening study identifying
early detection biomarkers showed several molecules
involved in OC development, including PNPO. Currently,
only three publications exist regarding a relationship
between PNPO and cancer. The ﬁrst report was published in
1998 describing the absence of PNPO activity in liver and
brain tumours20. Nine years later in 2006, another report
showed that PNPO is induced by estradiol and 4-
hydroxytamoxifen in T47D and MCF7 breast cancer cells,
but not in ERα-negative MDA-MB-231 breast cancer cells19.
During the preparation of this manuscript, a new study
reported that PNPO is one of seven genes that can predict
overall survival of patients with colorectal cancer21. These
data suggest that PNPOmay be implicated in tumorigenesis.
Yet, none of these studies explored the mechanisms of how
PNPO is regulated in cancer.
Our study provides the evidence of PNPO over-
expression in the tumour tissues of human EOC, including
serous, mucinous, endometrioid, transitional cell and clear
cell carcinoma. The expression of PNPO protein was sig-
niﬁcantly correlated with age, histological type and grade.
Higher levels of PNPO expression were found in surface
epithelial malignant tumours rather than sex cord-stromal
and germ cell tumours, indicating that the overexpression
of PNPO may be EOC speciﬁc. Furthermore, PNPO
expression was increased with age and grade, suggesting
that PNPO may play a role in EOC development. Our data
are consistent with a cohort of data sets found in Onco-
mine, which PNPO mRNA was higher in serous, muci-
nous, endometrioid and clear cell carcinomas compared
with the normal ovary. These data further conﬁrm the
overexpression of PNPO in OC, indicating that PNPO may
play a role in OC development. In the future, nevertheless,
it may be of interest to examine PNPO expression in
patients following treatment and to measure secreted
PNPO in the serum and urine of patients to see if PNPO as
a biomarker of EOC can be detected in body ﬂuids.
The function of PNPO in cancer, especially in EOC, had
not been reported before. Using a loss-of-function
approach we examined the biological functions of
PNPO in vitro and in vivo, speciﬁcally apoptosis, pro-
liferation, migration, invasion and colony formation in
EOC cells. Knockdown of PNPO induced cell apoptosis
and decreased cell proliferation, migration and invasion.
Furthermore, silencing of PNPO inhibited tumour
(see ﬁgure on previous page)
Fig. 5 Suppression of tumour growth after knockdown of PNPO in nude mice. Mice were implanted with either PNPO-shRNA-expressing cells
(PNPO-shRNA) or negative control cells (NC) of SK-OV-3 and live for 40 days. a Photograph of excised tumour mass after the killing (n = 14).
b Quantitative analysis of individual tumour volume in PNPO-shRNA and NC xenografts. c Live measurement of tumour volume in a time-course
study. d Live measurement of mouse weight in a time-course study. e PNPO protein expression in tumour mass detected by western blot using a
speciﬁc antibody against human PNPO. Arabic numerals represent the case number. The parental SK-OV-3 cells were used as positive control of
detection (n = 2). f Semi-quantitative analysis of the relative optical density of protein bands in e. Data are presented as mean ± SEM (n = 5). g
Tumour tissue sections were subjected to IHC for analysis of Ki-67 and PNPO expression. Representative images of Ki67 and PNPO expression in
PNPO-shRNA and NC cells are shown. Original ampliﬁcation, ×200, ×400 (insert). Scale bar, 100 µm. h Quantitative analysis of the percentage of Ki-67-
positive cells. i Quantitative analysis of the percentage of PNPO-positive cells. *P < 0.05; **P < 0.01
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formation in the orthotopically implanted nude mice.
These data, along with the observation of PNPO over-
expression in human tumour tissues, suggest that PNPO
may contribute to OC progression.
In vitamin B6 metabolism, PN and PM from food and
dietary supplements are precursors of PNP and PMP that
are oxidized into PLP by PNPO and ﬁnally metabolized into
PL36. PLP is an active form of vitamin B6 and it has been
estimated that about 4% of all enzyme activities use PLP as a
cofactor37. Our study unveiled that increased PLP can sup-
press PNPO protein expression, resulting in the inhibition of
EOC cell proliferation. These data may suggest that PLP is
important for the regulation of PNPO expression, in addi-
tion to it being a product of PNP/PMP oxidation by PNPO.
A feedback loop between PLP and PNPO may exist, but the
mechanism how PLP regulates PNPO expression remains
unclear and thus requires further study.
Increasing evidence shows that TGF-β signalling plays
an important role in the development of OC38,39.
Alteration of TGF-β signalling is crucial for ovarian
tumorigenesis40. Our previous studies have shown that
TGF-β1 regulates cystatin B30, β-2-microglobulin29 and
CMPK131, three progression markers of the human epi-
thelial ovarian tumour. The current study also demon-
strated that PNPO is another EOC progression marker
regulated by the TGF-β signalling pathway. We found that
TGF-β1 upregulated miR-143-3p and that PNPO was a
target gene of miR-143-3p. These data suggest that the
downregulation of PNPO expression by TGF-β1 is at least
in part via the upregulation of miR-143-3p. We speculate
that the loss of TGF-β responsiveness or a defect in TGF-
β signalling may lead to the downregulation of miR-143-
3p and, in turn, the upregulation of PNPO. Interestingly,
we found that knockdown of PNPO increased the phos-
phorylation of Smad2, most likely due to the negative
feedback loop between PNPO and TGF-β signalling.
The current study utilized clinical samples that showed
a slight negative-correlation between PNPO and its reg-
ulator miR-143. It has been shown that a chemically
modiﬁed miR-143 signiﬁcantly suppresses the tumour
formation in a colorectal cancer model41. Thus, we
speculate that PNPO and its regulators are the candidates
of a potential target for the treatment of EOC.
In summary, we have demonstrated for the ﬁrst time
that PNPO is overexpressed in human EOC, suggesting
that PNPO may be a useful tissue biomarker of OC.
PNPO is downregulated by the TGF-β signalling pathway
through the upregulation of miR-143-3p. Silencing of
PNPO induces OC cell apoptosis and decreases cell pro-
liferation, migration and invasion in vitro and tumour
formation in vivo. A schematic illustration of the
mechanisms of PNPO regulation and intracellular con-
version of vitamin B6 vitamers is shown in Fig. 8. Based
on the fact that decreased PNPO resulted in a change of
cell behaviour, we predict that PNPO may be a potential
diagnostic biomarker and therapeutic target in patients
with EOC. Inhibition of PNPO by the administration of
miRNA, RNAi and PLP may be a good therapeutic
strategy against OC.
Methods
Patients and ovarian tissue samples
Informed consent was obtained from patients and ethics
approval was obtained from the Ethics Committee of Jin-
shan Hospital, Fudan University. Cytoreductive surgery was
performed on 73 patients at Jinshan Hospital from January
2005 to December 2013. Patients had not received che-
motherapy or radiotherapy before surgery. Ovarian tissue
samples were obtained from patients with ovarian tumour
(24 benign cases, 18 borderline cases and 31 malignant
cases). Control ovarian tissues were obtained from nine
patients with non-tumorous ovaries. Ovarian tissues were
formalin-ﬁxed, parafﬁn embedded or frozen for subsequent
histological and biochemistry analyses, respectively.
Pathology assessment
Formalin-ﬁxed, parafﬁn embedded ovarian tissue speci-
mens underwent pathological examination in the Depart-
ment of Pathology, Jinshan Hospital. Histological grades
and stages were classiﬁed based on the current criteria of
tumour, node and metastasis (TNM) classiﬁcation from
the American Joint Committee on Cancer (AJCC) and the
World Health Organization (WHO). The ﬁnal diagnosis of
disease was made by experienced gynaecologists and
pathologists according to the FIGO (International Fed-
eration of Gynaecological Oncologists) system.
(see ﬁgure on previous page)
Fig. 6 Effect of vitamin B6 on PNPO expression and cell proliferation. a, b Concentration of vitamin B6 vitamers (PLP, PL, PN and PM) in the
cytosol and culture medium of three epithelial ovarian cell lines HOSEpiC (HOS), OVCAR-3 (OV) and SK-OV-3 (SK). c Dose-dependent effect of PLP on
PNPO protein expression in SK-OV-3 cells. Cells were treated with 0, 0.05, 0.5 and 5 mg/ml of PLP for 48 h. PNPO protein expression was detected by
western blot. d Time-course effect of PLP on PNPO protein expression in SK-OV-3 cells. Cells were treated with 0.5 mg/ml of PLP for 24 and 48 h.
PNPO protein expression was detected by western blot. e PNPO protein expression in SK-OV-3 and OVCAR-3 cells after 0.5 mg/ml of PLP treatment
for 48 h. f Semi-quantitative analysis of the relative optical density (ROD) of protein bands in e, g PNPO expression in SK-OV-3 and OVCAR-3 cells after
0.5 mg/ml of PN treatment for 48 h. h Semi-quantitative analysis of the ROD of protein bands in g, i, j Measurement of cell proliferation. SK-OV-3 and
OVCAR-3 cells were treated with PLP, PN or vehicle HCl for 24, 48 and 72 h. Untreated cells were used as control (blank). Cell proliferation was
detected by the WST-1 assay. Data are presented as mean ± SEM. *P < 0.05; **P < 0.01; n = 3 independent experiments
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Tissue microarray
Ovarian tissue microarrays (Cat# OV20813 and Cat#
OC 20814, Xi’an Alena Biotechnology Co. Ltd., Xi’an,
China) were used for the IHC analysis. A total of 416
parafﬁn-embedded ovarian tissue samples from indivi-
duals with a median age of 48 years (range 11–88 years)
were collected and of these, 404 samples were valid (388
malignant tumours, 7 normal ovarian tissues and 9
Fig. 7 Regulation of PNPO expression by the TGF-β signalling pathway. a, b, c Effect of TGF-β1 on PNPO expression. SK-OV-3 and OVCAR-3 cells
were treated with TGF-β1 at different concentrations (0, 1, 10 ng/ml). a PNPO mRNA expression was detected after 24 h treatment. b PNPO protein
expression was detected after 48 h treatment. c Semi-quantitative analysis of the relative optical density of protein bands in b (n = 3). d, e, f Effect of
TGF-β type I receptor kinase inhibitor SB431542. Cells were pre-treated with 10 µM SB431542 for 30 min and then treated with 1 ng/ml of TGF-β1. d
PNPO mRNA expression was detected after TGF-β1 treatment for 24 h. e PNPO protein expression was detected after TGF-β1 treatment for 48 h. f
Semi-quantitative analysis of the relative optical density of protein bands in e (SK-OV-3, n = 5; OVCAR-3, n = 4). Phospho-Smad2 (p-Smad2) and β-
actin were used as controls in western blot analysis. g A schematic diagram illustrated the sequences of the putative miR-143-3p binding site in the
PNPO 3′-UTR and its mutant. h Dual-luciferase reporter assay. The interaction of miR-143-3p with the PNPO mRNA at 3′-UTR in HEK293T cells was
conﬁrmed (n = 3). i Effect of miR-143 mimics (50 nM for 72 h) on PNPO protein expression detected by western blot in OVCAR-3 cells. j Semi-
quantitative analysis of the relative optical density of protein bands in I (n = 3). k Effect of miR-143 inhibitor (anti-miR-143) (150 nM for 72 h) on PNPO
protein expression detected by western blot in OVCAR-3 cells. l Effect of TGF-β1 (0, 1 and 10 ng/ml for 3 h) on primary miR-143 (Pri-miR-143)
expression detected by qRT-PCR in OVCAR-3 cells.m Effect of TGF-β1 (0, 1 and 10 ng/ml for 3 h) on mature miR-143 expression detected by qRT-PCR
in OVCAR-3 cells. Data are presented as mean ± SEM. *P < 0.05; **P < 0.01
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adjacent normal tissues of OC) and 12 samples were
either invalid or missing after IHC. Clinical characteristics
including age, histological type, grade, stage and lymph
node metastasis were recorded.
Immunohistochemical staining and analysis of human
ovarian tissue
Immunohistochemistry was performed as described
previously30. After blocking with 10% normal goat serum
(Maixin Bio, Fuzhou, Fujian, China) for 40 min at room
temperature, sections were incubated at 4 °C overnight
with a monoclonal mouse anti-PNPO antibody (1:300
dilution, Abcam, New Territories, Hong Kong, China),
followed by incubation at room temperature for 1 h with
biotinylated anti-mouse secondary antibody (Maixin Bio).
The immunoreactive signal was detected using a DAB Kit
(Maixin Bio). Sections were then counterstained with
hematoxylin and photographed under a light microscope
(BX43, OLYMPUS, Tokyo, Japan) at ×100 and ×400
magniﬁcation. Brown colour staining in the cell was
considered as PNPO-positive staining. Evaluation of
immunoreactive staining was performed by two patholo-
gists without any prior knowledge of the patient’s clinical
data. Pathologists then resolved initial discordant staining
scores through discussion and consensus. A staining index
(SI)30 was determined by the sum of the positive extent and
staining intensity and expressed as PNPO-negative and
PNPO-positive. In brief, the percentage of PNPO immuno-
positive cells were scored as 0 (no positive cell), 1 (⩽25%
positive cells), 2 (26–50% positive cells), 3 (51–75% positive
cells) and 4 (>75% positive cells). The intensity of immu-
noreactive staining was also scored as 0 (no staining), 1
(weak staining), 2 (moderate staining) and 3 (strong stain-
ing). A ﬁnal immunoreactive score, referred to SI, was
determined by the sum of the immuno-positive cells and
staining intensity, and was clustered into four groups: '0',
⩽2 sum points; '1', 3–4 sum points; '2', 5–6 sum points; and
'3', 7 sum points. Cases with a ﬁnal SI score of 0 and 1 were
classiﬁed as PNPO-negative and the cases with a ﬁnal SI
score of 2 and 3 were classiﬁed as PNPO-positive.
Cell culture
Human OC cell lines OVCAR-3 (adenocarcinoma), SK-
OV-3 (adenocarcinoma), CAOV-3 (adenocarcinoma) and
ES-2 (clear cell carcinoma) cells were purchased from
American Type Culture Collection (ATCC, Mana-
ssas, VA, USA). Human ovarian carcinoma cell line
A2780 was purchased from the European Collection of
Authenticated Cell Cultures (ECACC, UK). OVCAR-3
and A2780 cells were cultured in RPMI-1640 and SK-OV-
3 and CAOV-3 cells were cultured in Dulbecco's Modiﬁed
Eagle's Medium (DMEM, 4.5 g/L glucose, Corning Inc.,
Manassas, VA, USA) supplemented with 10% fetal bovine
serum (FBS, Invitrogen, Carlsbad, CA, USA). ES-2 cells were
cultured in McCoy’s 5A medium (Sigma, Saint Louis, MO,
USA) supplemented with 10% FBS. Non-tumorous human
ovarian surface epithelial cells (HOSEpiC) as control cells
were obtained from Guangzhou Jennio Biotech Co., Ltd
(Guangzhou, Guangdong, China) and cultured in RPMI-
1640 medium supplemented with 10% FBS. Dulbecco's
Modiﬁed Eagle's Medium (DMEM), ethylenediaminete-
traacetic acid (EDTA),phenylmethylsulfonyl ﬂuoride (PMSF)
PNPO-siRNA transfection
For transient transfection of siRNA, cells were ﬁrst
seeded in a six-well plate at a density of 2×105 (OVCAR-3
Fig. 8 Schematic illustration of the mechanism of PNPO
regulation and the intracellular conversion of vitamin B6
vitamers in ovarian cancer cells. TGF-β1 binds to its type II receptor
and recruits type I receptor to form a receptor complex, which then
phosphorylates and activates intracellular transducer protein Smad2.
MiR-143-3p is upregulated upon TGF-β1 stimulation and interacts with
the 3′-UTR of PNPO mRNA, leading to a downregulation of PNPO
expression. Blocking type I receptor by SB-431542 abolishes the TGF-β
action. PNPO is upregulated in epithelial ovarian cancer cells.
Knockdown of PNPO by RNA interference results in the inhibition of
cell proliferation, migration and invasion, the induction of apoptosis,
the retard of tumour formation and a negative feedback loop with
Smad2 phosphorylation. Dietary pyridoxine (PN) and pyridoxamine
(PM) serve as the main source of pyridoxine 5′-phosphate (PNP) and
pyridoxamine phosphate (PMP). PNP and PMP are then converted to
pyridoxal 5′-phosphate (PLP), an active form of vitamin B6, by the
catalysing enzyme - pyridoxine 5′-phosphate oxidase (PNPO). PLP is
ﬁnally hydrolysed to pyridoxal (PL). Increased PLP inhibits PNPO
expression and cell proliferation
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cells) or 1.5×105 (SK-OV-3 cells) per well for 24 h. In
order to determine the knockdown efﬁciency of PNPO by
PNPO-speciﬁc short interfering RNA (siRNA) for sub-
sequent experiments, cells were transiently transfected
with three different PNPO-siRNAs and an NC siRNA
(GenePharma Co., Ltd., Shanghai, China) (Supplementary
Table S2), respectively, at a ﬁnal concentration of 2 µg/
well for 6 h using X-tremeGENE siRNA Transfection
Reagent (Roche Diagnostics, Indianapolis, IN, USA) as
described by the manufacturer’s instructions, followed by
western blot.
Generation of PNPO-shRNA construct and PNPO-shRNA
expressing cells
Human PNPO short hairpin RNA (PNPO-shRNA,
shPNPO) was constructed with double-strand oligonucleo-
tides corresponding to the target sequence of
GACTGGCTCTATGAGAGAC and inserted into pHY-LV-
KD5.1 RNAi lentivirus (Hanyin Biotechnology Co., Ltd.,
Shanghai, China). The sense and antisense sequences of
PNPO-shRNA are listed in Supplementary Table S2.
To generate PNPO-shRNA-expressing cells and their
counterpart control cells, OVCAR-3 and SK-OV-3 cells were
seeded in six-well plates and infected with PNPO-shRNA or
control lentiviral particles at a concentration of 15 and 20
multiplicity of infection, respectively, with polybrene at a ﬁnal
concentration of 8 µg/ml. After incubation for 24 h, cells were
washed and cultured with medium supplemented with 3 µg/
ml of puromycin (to kill uninfected cells). The efﬁciency of
PNPO-shRNA lentiviral transduction was examined by
ﬂuorescence microscopy as the constructs contained GFP.
Knockdown of PNPO was conﬁrmed by qRT-PCR and
western blot. The fourth or ﬁfth passaged cells that stably
expressed PNPO-shRNA were used for cellular assays.
RNA extraction and quantitative real-time PCR
Total RNA was extracted from tissues and cells using
Trizol (Invitrogen) according to the manufacturer’s
instruction and as described previously30. PCR primer
sequences (Supplementary Table S2) were synthesized
by Sangon Biotech Co., Ltd. (Shanghai, China). Reaction
conditions of cDNA synthesis were as 30 °C for 10 min,
42 °C for 50 min, 85 °C for 5 min, 4 °C for 60 min. PCR
ampliﬁcation was performed at 95 °C for 10 min, fol-
lowed by 40 cycles of 95 °C for 10 s and 60°C for 31 s
using an SYBR Green Master kit (Roche Applied Sci-
ence). Samples were run in triplicate and experiments
were repeated at least three times. The expression level
of PNPO mRNA normalized to an endogenous control
β-actin or target miRNA normalized to its control U6
was calculated using 2ΔΔCt, in which threshold cycle (Ct)
was obtained using Sequence Detection Software V1.4
(7300 Real Time PCR System, Applied Biosystems,
Foster City, CA, USA).
Protein extraction and western blot analysis
PNPO-shRNA and control cells and ovarian tissues
were lysed in sodium dodecyl sulfate (SDS) lysis buffer
(Beyotime, Haimen, Jiangsu, China) with 1% phe-
nylmethylsulfonyl ﬂuoride (PMSF, Beyotime) and 1%
phosphatase inhibitor (Key-GEN), followed by sonication
and SDS-polyacrylamide gel electrophoresis. The follow-
ing primary antibodies were used: mouse anti-PNPO
(1:4000 dilution, Abcam), rabbit anti-Bcl-2 (1:1000 dilu-
tion, Santa Cruz), mouse anti-Smad 2 (1:2000 dilution),
rabbit anti-phospho-Smad2 (1:1000 dilution), rabbit
caspase-3 (1:1000 dilution), rabbit anti-Bax (1:1000 dilu-
tion) and rabbit anti-β-actin (1:5000 dilution) (Cell Sig-
naling Technology, Inc., Danvers, MA, USA). Secondary
antibodies were horseradish peroxidase-conjugated goat
anti-rabbit IgG and anti-mouse IgG (1:10,000 dilution,
Cell Signaling Technology, Inc.). Signals were detected
using ImmobilonTM Western Chemiluminescent HRP
Substrate (Millipore) and quantiﬁed using Tanon-4500
Gel Imaging System with GIS ID Analysis Software v4.1.5
(Tanon Science & Technology Co., Ltd., Shanghai, China).
Cell proliferation and cell cycle progression assays
Control and PNPO-shRNA-expressing cells were see-
ded in 96-well plate at a density of 3×103/well (SK-OV-3)
or 5×103/well (OVCAR-3) and cultured for 24, 48 or 72 h.
Cell proliferation was detected by the WST-1 assay
(Roche Diagnostics, Indianapolis, IN, USA) according to
the manufacturer’s instruction.
Cell cycle was measured by ﬂow cytometry. In brief,
cells were seeded in six-well plates and cultured for 48 h.
After trypsinization, the cells were washed with cold
phosphate buffered saline (PBS) twice at 1000 rpm for 5
min each and ﬁxed with cold 70% ethanol. After washing
cells with PBS three times, the pellet was resuspended in
500 µl of propidium iodide (PI) solution (PI/RNase
Staining Buffer, BD Pharmingen, San Diego, CA, USA)
and incubated in the dark at room temperature for 15
min. Ten thousand cells were acquired by ﬂow cytometry
(Beckman Coulter, Inc., Brea, CA, USA). Flow data were
analysed using Wincycle software (Beckman Coulter) and
presented as the percentage of the cell population in G0/
G1, S and G2/M phases.phosphate buffered saline (PBS)
Migration assay
To assess whether PNPO silencing impacts cell migra-
tion, wound healing and transwell migration assays were
conducted. To measure the wound-ﬁll rate in vitro,
PNPO-shRNA-expressing cells and control cells were ﬁrst
cultured, respectively, in six-well plates and grew until
subconﬂuence. An approximately 800-μm-wide wound in
the plate was created by scraping the monolayer with a
sterile 200-µl pipette tip. The width of the gap in the
monolayer was photographed under a microscope and
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measured using CellSens Life Science Imaging Software
(OLYMPUS).
Transwell migration assay was performed in a 24-well
transwell chamber with a polycarbonate membrane (6.5
mm in diameter with 8-μm pores, Costar Corning, New
York, NY, USA). In brief, cells were plated into the upper
chamber at a density of 5×103 cells/well with 800 µl of
medium without serum. The lower chamber was ﬁlled
with 600 µl of medium containing 10% FBS. After incu-
bation for 24 or 48 h, cells that had not migrated to the
bottom chamber were gently removed from the upper
chamber by a swab. Cells that migrated through the
membrane were ﬁxed with 4% paraformaldehyde, stained
with 5% Crystal Violet Staining Solution (Beyotime), and
photographed under a light microscope (OLYMPUS) at
×400 magniﬁcation.
Invasion assay
The extent of invasive migration of PNPO-silenced cells
was assessed using a standard invasion assay. Matrigel
(ﬁnal concentration 250 µg/ml, BD Biosciences #356234,
Bedford, MA, USA) was coated on the top of a poly-
carbonate membrane before seeding the PNPO-shRNA-
expressing and NC cells. The cells were plated into the
upper chamber at a density of 5×103 cells/well and cul-
tured under the same conditions as described in the
migration assay. After 24 or 48 h, cells that had not
invaded the bottom chamber were gently removed from
the upper chamber by a swab. Cells that invaded through
the membrane were ﬁxed, stained, photographed and
counted as in migration assay.
Detection of apoptosis
Apoptotic cells were detected by staining EOC cells
with annexin-V conjugated with APC (Allophycocyanin,
BD Pharmingen, BD Biosciences) and PI (BD Pharmin-
gen). In brief, cultured cells were trypsinized (in the
absence of ethylenediaminetetraacetic acid, EDTA) and
washed twice with cold PBS. Cells were then resuspended
in 1× binding buffer at a density of 1×106cells/ml. After
transferring 100 µl of cell
suspension into a 5 ml tube, 5 µl of APC Annexin-V and/
or 5 µl of PI was added. Cells were then incubated in the
dark for 15min at room temperature. After adding 400 µl
of 1× binding buffer to each tube, the cell population was
immediately measured by ﬂow cytometry.
Determination of PNPO activity
PNPO activity was determined by measuring vitamin B6
vitamers in PNPO-shRNA and control SK-OV-3 cell
lysates and culture medium using Liquid Chromatogram
(Waters®Xevo®TQ-Smicro, Milford, MA, USA). Standard
curves of PLP, pyridoxine (PN), pyridoxamine (PM) and
pyridoxal (PL) were generated using commercial
products. Five microliters of standards and samples were
respectively added into a liquid chromatogram. The
concentrations of different vitamers in cell lysates and
culture media were quantiﬁed and PNPO activity was
indirectly determined by the amount of upstream and
downstream vitamers.
Treatment with TGF-β1 and its receptor inhibitor
After seeding for 24 h, PNPO-shRNA-expressing cells
and control cells were treated with recombinant human
TGF-β1 (R&D Systems, Minneapolis, MN, USA) at 0, 1 or
10 ng/ml for 24 or 48 h. To block TGF-β signalling, cells
were pre-treated for 30min with 10 µM SB-431542 (Sigma),
a TGF-β type I receptor kinase inhibitor42, which was dis-
solved in dimethyl sulfoxide (DMSO) at a concentration of
10mM, and then treated with TGF-β1 for 24 h (mRNA) or
48 h (protein). DMSO was used as a treatment control.
Transfection of microRNA mimics/inhibitors and
dual-luciferase reporter assay
After seeding at a density of 2×105 cells/well into a six-
well plate and incubation for 16 h, OVCAR-3 cells were
transfected with 50 nM miR-143-3p mimics, 50 nM miR-
negative control (miR-Ctrl), 150 nM miR-143-3p inhibi-
tors (anti-miR-143) or 150 nM anti-miR-negative control
(anti-miR-Ctrl) (Supplementary Table S2) (RiboBio Co.,
Ltd, Guangzhou, Guangdong, China) using X-
tremeGENE Transfection Reagent (Roche Applied Sci-
ence) and cultured for 72 h.
A partial 3′-UTR of PNPO (479 bp) that contains the
predicted binding site of miR-143-3p was ampliﬁed
from genomic DNA by using the Pfu Ultra II Fusion HS
DNA Polymerase (Stratagene, Agilent Technologies,
Santa Clara, CA, USA) with speciﬁc primers (Supple-
mentary Table S2). The PCR product was inserted into
a Duo-Luciferase reporter vector pEZX-FR2 (Gene-
Copoeia Inc, Rockville, MD, USA) after linearizing by
EcoRI and XhoI restriction enzymes using EasyGeno
Assembly Cloning kit (Tiangen Biotech Co., Ltd, Beij-
ing, China), which was named as pEZX-PNPO. The 3′-
UTR mutant pEZX-PNPOmut was generated in the
consensus miR-143-3p binding site by using a Quik-
Change II site-directed mutagenesis kit (Stratagene).
All constructs were veriﬁed by restriction enzyme
digestion and DNA sequencing. To determine the
expression of our clone, subconﬂuent HEK293T cells
were cultured in 24-well plates and co-transfected with
0.5 µg pEZX-PNPO (or pEZX-PNPOmut) reporter
plasmid and 50 nM miR mimics (or NCs) using Roche
X-tremeGENE Transfection Reagent. After 24 h, cells
were lysed and luciferase activities were deter-
mined using Luc-Pair™ Duo-Luciferase Assay Kit
(GeneCopoeia Inc) according to the manufacturer’s
instructions.
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Tumour xenograft mouse model
Animal ethics was granted by the Ethics Committee of
Jinshan Hospital, Fudan University. Female 6- to 8-week-
old BALB/c nude mice (Shanghai Super-B&K Laboratory
Animal Corp. Ltd., Shanghai, China) were randomly
divided into two groups: one group that received PNPO-
shRNA-expressing cells (PNPO-shRNA) and the second
group that received the parental SK-OV-3 NC cells (n=
14 per group). Animals were housed under standard 12/
12 h light/dark cycle with free access to food and water.
After culture, subconﬂuent PNPO-shRNA-expressing
cells and control SK-OV-3 cells were resuspended,
respectively, in DMEM without FBS. Approximately
5×106 cells in 150 µl were injected into the right ﬂank of
each mouse. Body weight, tumour initiation and tumour
progression were monitored every another day for 40 days
(day of the ﬁrst injection= day 0). Tumour volume was
calculated using the formula V= ab2/243, where V is the
volume, and a and b represent the tumour length and
width, respectively. On day 40, animals were killed. Whole
tumours were excised and photographed.
Statistical analyses
All analyses were performed using SPSS Statistics 21.0 for
Windows (SPSS, Chicago, IL, USA). For comparison of
PNPO expression associated with the clinicopathological
characteristics of patients with EOC, a Fisher’s exact test or
χ2 test was applied. For comparison between two groups in
functional assays, vitamer detecting assays and treatment
experiments, a Student t-test was used. Results are presented
as the mean±standard error of the mean (SEM). A sig-
niﬁcant difference was considered at the value of P< 0.05.
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